SEARCH

SEARCH BY CITATION

References

  • 1
    Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 35: 958965.
  • 2
    Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis c virus infection. N Engl J Med 2002; 347: 975982.
  • 3
    Jeffers L, Cassidy W, Howell CD, Hu S, Reddy KR. Peginterferon alfa-2a and ribavirin for black American patients with chronic HCV genotype 1. HEPATOLOGY 2004; 39: 17021708.
  • 4
    Muir AJ, Bornstein JD, Killenberg PG. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-hispanic whites. N Engl J Med 2004; 350: 22652271.
  • 5
    Buti M, Valdes A, Sanchez-Avila F, Esteban R, Lurie Y. Extending combination therapy with peginterferon alfa-2b plus ribavirin for genotype 1 chronic hepatitis C late responders: a report of 9 cases. HEPATOLOGY 2003; 37: 12261227.
  • 6
    Ferenci P, Fried MW, Shiffman ML, Smith CI, Marinos G, Goncales FL Jr, et al. Predicting sustained virological responses in chronic hepatitis c patients treated with peginterferon alfa-2a/ribavirin. J Hepatol 2005; 43: 425433.
  • 7
    Davis GL, Wong JB, McHutchison JG, et al. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. HEPATOLOGY 2003; 38: 645652.
  • 8
    Berg T, Von Wagner M, Nasser S, Sarrazin C, Heintges T, Gerlach T, et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006; 130: 10861097.
  • 9
    Sanchez-Tapias JM, Diago M, Escartin P, Enriquez J, Romero-Gomez M, Barcena R, et al. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 2006: 131: 451460.
  • 10
    National Institutes of Health Consensus Development Conference Statement: management of hepatitis C 2002. HEPATOLOGY 2002; 36: S3S20.
  • 11
    Drusano GL, Preston SL. A 48-week duration of therapy with pegylated interferon alfa-2b plus ribavirin may be too short to maximize long-term response among patients infected with genotype-1 hepatitis virus. J Infect Dis 2004; 189: 964970.
  • 12
    Reichard O, Foberg U, Fryden A, Mattsson L, Norkrans G, Sonnerborg A, et al. High sustained response rate and clearance of viremia in chronic hepatitis C after treatment with interferon alfa-2b for 60 weeks. HEPATOLOGY 1994; 19: 280285.
  • 13
    Poynard T, Bedossa P, Chevallier M, Mathurin P, Lemonnier C, Trepo C, et al. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. N Engl J Med 1995; 332: 14571462.
  • 14
    Brouwer JT, Nevens F, Bekkering FC, Bourgeois N, Van Vlierberghe H, Weegink CJ, et al. Reduction of relapse rates by 18-month treatment in chronic hepatitis C. A Benelux randomized trial in 300 patients. J Hepatol 2004; 40: 689695.
  • 15
    Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346355.
  • 16
    Bressler BL, Guindi M, Tomlinson G, Heathcote J. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. HEPATOLOGY 2003; 38: 639644.
  • 17
    Conjeevaram HS, Fried MW, Jeffers LJ, Terrault NA, Wiley-Lucas TE, Afdhal N, et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006; 131: 470–477.
  • 18
    Reddy KR, Shiffman ML, Morgan TR, Zeuzem S, Hadziyannis S, Hamzeh FM, et al. Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. Clin Gastroenterol Hepatol 2007; 5: 124129.
  • 19
    Shiffman ML, Ghany MG, Morgan TR, Wright EC, Everson GT, Lindsay KL, et al. Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology 2007; 132: 103112.
  • 20
    Cooper CL, Al-Bedwawi S, Lee C, Garber G. Rate of infectious complications during interferon-based therapy for hepatitis C is not related to neutropenia. Clin Infect Dis 2006; 42: 16741678.
  • 21
    Soza A, Everhart JE, Ghany MG, Doo E, Heller T, Promrat K, et al. Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. HEPATOLOGY 2002; 36: 12731279.
  • 22
    Pearlman BL. Hepatitis C virus infection in African Americans. Clin Infect Dis 2006; 42: 8291.
  • 23
    Buti M, Lurie Y, Blokhina N, Teuber G, Halota W, Sumskiene J, et al. Pegylated interferon alfa-2b plus ribavirin in patients with genotype 1 chronic hepatitis C with a slow virologic response: an early enrollers analysis of the SUCCESS Study [Abstract]. HEPATOLOGY 2006; 44( Suppl): 342A.